Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Paolo Cravedi; Varusca Brusegan; Piero Ruggenenti; Ruth Campbell; Giuseppe Remuzzi

doi:10.3390/ph3010001

Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, Ruth Campbell, Giuseppe Remuzzi

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

Original language	English
Pages (from-to)	1-9
Number of pages	9
Journal	Pharmaceuticals
Volume	3
Issue number	1
DOIs	https://doi.org/10.3390/ph3010001
Publication status	Published - 2010

Keywords

Hyperkalemia
Idiopathic membranous nephropathy
Proteinuria
Spironolactone

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science

Access to Document

10.3390/ph3010001

Cite this

@article{2f065818acd142afb44839020fe158d8,

title = "Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?",

abstract = "We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure ",

keywords = "Hyperkalemia, Idiopathic membranous nephropathy, Proteinuria, Spironolactone",

author = "Paolo Cravedi and Varusca Brusegan and Piero Ruggenenti and Ruth Campbell and Giuseppe Remuzzi",

year = "2010",

doi = "10.3390/ph3010001",

language = "English",

volume = "3",

pages = "1--9",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome

T2 - Does it really work?

AU - Cravedi, Paolo

AU - Brusegan, Varusca

AU - Ruggenenti, Piero

AU - Campbell, Ruth

AU - Remuzzi, Giuseppe

PY - 2010

Y1 - 2010

N2 - We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

AB - We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

KW - Hyperkalemia

KW - Idiopathic membranous nephropathy

KW - Proteinuria

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=77951926399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951926399&partnerID=8YFLogxK

U2 - 10.3390/ph3010001

DO - 10.3390/ph3010001

M3 - Article

AN - SCOPUS:77951926399

SN - 1424-8247

VL - 3

SP - 1

EP - 9

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 1

ER -

Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this